|
|
|
| |
World's one of the largest Research
Career Network |
|
|
|
Benefits |
- Academic & Industry jobs
- Project funding
- Visiting faculty positions
- Visiting scientist positions
- Invited talks
- and more...
|
|
|
|
|
|
|
|
Register FREE
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Global Journal of Biochemistry. Volume 2, Issue 4 (2011) pp. 250-261
|
|
|
Review Article
|
Free Article
|
|
|
|
|
|
Dysregulation of mTOR pathway component in breast cancer and mTOR inhibitors in breast cancer therapy
|
|
|
|
Jun Lin, Xiaochun Bai
|
|
|
|
|
|
|
|
Department of Cell Biology, School of Basic Medical Science, Southern Medical University
Guangzhou 510515, China
|
|
|
|
|
|
|
|
Abstract |
|
|
|
In breast cancer, the phosphatidylinositol 3-kinases (PI3K)/Akt/mammalian target of rapamycin (mTOR) pathway can be activated by several membrane receptors, including the human epidermal growth factor receptor (HER) family, the insulin-like growth factor (IGF) receptor, and the estrogen receptor (ER), thus plays a critical role in tumorigenesis, progression and development of endocrine resistance. mTOR, the central modulator of this pathway, gained increasing more attention as a potent anti-cancer target. In this review, we summarize the dysregulation of key components of mTOR pathway in breast cancer and their prognostic values, and the clinical application of mTOR inhibitors, with special emphasis on the latest achievement in the recent years.
|
|
|
|
|
|
|
Keywords |
|
|
|
Mammalian target of rapamycin; Breast cancer
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|